Sou Hu Cai Jing·2026-01-10 20:33Core Viewpoint - *ST Bio has experienced a decline in stock price and is facing significant challenges, including a warning of potential delisting due to negative net profit and insufficient revenue for 2024 [1][4]. Company Announcements - *ST Bio plans to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. in cash, which will constitute a major asset restructuring [2][4]. - The company and its subsidiaries will engage in lithium carbonate futures hedging, with a maximum margin balance of 3 million RMB and a maximum contract value of 30 million RMB on any trading day [1][2]. - Due to a negative net profit for 2024 and revenue below the required standard, *ST Bio's stock has been placed under delisting risk warning [2][4]. Governance and Compliance - The company has established a "Commodity Futures Trading Management System" to ensure trading is solely for hedging purposes, with regular audits and risk control assessments [2]. - A "Board and Senior Management Departure System" has been implemented, detailing the process for resignations and the obligations of departing personnel [3].